A doctor writes tuberculosis prevention information on the health bulletin board at his clinic in Yangang Village of Yudu County, east China's Jiangxi Province, Aug. 15, 2023. (Xinhua/Hu Chenhuan)
China's self-developed novel tuberculosis mRNA vaccine
started a clinical trial at Beijing Chest Hospital on Monday, according to the
local newspaper Beijing Evening News.
Previous animal experiments have shown that the
protective efficacy of the new vaccine is more than 20 times higher than that
of both Bacillus Calmette-Guerin (BCG) and foreign tuberculosis vaccines.
This tuberculosis vaccine with independent
intellectual property rights can offer a new vaccination option for people of
all age groups and effectively reduce the incidence and infection rates of
tuberculosis.
Next, the research and development team will
study the vaccine's immunization strategies, immune methods, administration
routes, and symptoms of vaccine adaptation, head of the hospital's
bacteriological immunology Pang Yu was quoted as saying by the newspaper.
Meanwhile, the hospital launched an AI diagnosis
model and a rapid detection method of tubercle bacillus bacteria based on
tongue swabs.
The diagnosis model can achieve remote,
non-invasive early detection of pulmonary diseases including tuberculosis. It
is currently in the preclinical stage, while the rapid detection method is
expected to be gradually promoted across the country starting from July,
according to the report.
https://english.news.cn/20250324/158f574cc0f1471bbfa01956ec4982ce/c.html
No comments:
Post a Comment